SG11201407981RA - Compositions comprising an anti-pdgf aptamer and a vegf antagonist - Google Patents

Compositions comprising an anti-pdgf aptamer and a vegf antagonist

Info

Publication number
SG11201407981RA
SG11201407981RA SG11201407981RA SG11201407981RA SG11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA SG 11201407981R A SG11201407981R A SG 11201407981RA
Authority
SG
Singapore
Prior art keywords
international
inventor
compositions
rule
executor
Prior art date
Application number
SG11201407981RA
Inventor
Byeong Seon Chang
Richard Everett
Original Assignee
Ophthotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophthotech Corp filed Critical Ophthotech Corp
Publication of SG11201407981RA publication Critical patent/SG11201407981RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181495 A2 (51) International Patent Classification: A61K39/395 (2006.01) A61K31/711 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043536 31 May 2013 (31.05.2013) English English (30) Priority Data: 61/654,672 61/778,208 1 June 2012 (01.06.2012) US 12 March 2013 (12.03.2013) US (71) Applicants: OPHTHOTECH CORPORATION [US/US]; 5 Vaughn Drive, Suite 106, Princeton, New Jer­ sey 08540 (US). EVERETT, Zoe (executor for the de­ ceased inventor) [US/US]; 25 Timber Lane, Randolph, New Jersey 07856 (US). GELTMAN, Marcia (executor for the deceased inventor) [US/US]; 20 Valley Road, Suite 300, Mount Arlington, New Jersey 07856 (US). GIELOW, Richard (executor for the deceased inventor) [US/US]; 2277 Oyster Bay Lane, #2104E, Gulf Shores, Alabama 36542 (US). (72) Inventor: EVERETT, Richard (deceased). (72) Inventor: CHANG, Byeong Seon; 14735 Sutton Street, Sherman Oaks, California 91403 (US). (74) Agents: LANGER, Matthew E. et al.; Cooley LLP, 1299 Pennsylvania Ave, Suite 700, Washington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17 : — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST FIG 77 < 1 o\ T-H 00 T-H rn i-H (57) Abstract: The present invention directed is to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In cer- O tain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease. N 10-2.5 10 0 0 Cone fnM)
SG11201407981RA 2012-06-01 2013-05-31 Compositions comprising an anti-pdgf aptamer and a vegf antagonist SG11201407981RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654672P 2012-06-01 2012-06-01
US201361778208P 2013-03-12 2013-03-12
PCT/US2013/043536 WO2013181495A2 (en) 2012-06-01 2013-05-31 Compositions comprising an anti-pdgf aptamer and a vegf antagonist

Publications (1)

Publication Number Publication Date
SG11201407981RA true SG11201407981RA (en) 2015-01-29

Family

ID=49674074

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407981RA SG11201407981RA (en) 2012-06-01 2013-05-31 Compositions comprising an anti-pdgf aptamer and a vegf antagonist

Country Status (18)

Country Link
US (1) US20150182623A1 (en)
EP (1) EP2854844A4 (en)
JP (1) JP2015519373A (en)
KR (1) KR20150033620A (en)
CN (1) CN104619335A (en)
AR (1) AR091237A1 (en)
AU (1) AU2013267310A1 (en)
CA (1) CA2874412A1 (en)
CL (1) CL2014003233A1 (en)
CO (1) CO7240393A2 (en)
EA (1) EA201492289A1 (en)
HK (1) HK1207983A1 (en)
IL (1) IL235797A0 (en)
MX (1) MX2014014445A (en)
PH (1) PH12014502577A1 (en)
SG (1) SG11201407981RA (en)
TW (1) TW201400122A (en)
WO (1) WO2013181495A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708882TA (en) 2013-07-12 2017-12-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2958017A1 (en) * 2014-08-11 2016-02-18 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
CN105435221B (en) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 Pharmaceutical composition of humanized antibody for vascular endothelial growth factor
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
CN105806830B (en) * 2015-12-10 2019-01-29 北京联众泰克科技有限公司 A kind of stable HRP enzyme-catalyzed chemical luminescence substrate liquid, preparation method and application
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2017213103B2 (en) * 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
BR112018014467A2 (en) * 2016-02-04 2018-12-11 Ni Jinsong drug-antibody synergism technology for disease treatment
CN108718522A (en) * 2016-02-23 2018-10-30 赛森生物股份有限公司 IL-6 antagonist formulations and application thereof
WO2018094316A1 (en) * 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
KR101861163B1 (en) * 2017-04-26 2018-05-25 삼천당제약주식회사 Ophthalmic pharmaceutical composition
US20210170029A1 (en) * 2017-11-20 2021-06-10 Just-Evotec Biologies, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
MX2020011848A (en) 2018-05-10 2021-03-29 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations.
WO2020087003A1 (en) * 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021125852A1 (en) * 2019-12-17 2021-06-24 주식회사 프로젠 Novel injectable formulation
AU2021232369A1 (en) * 2020-03-04 2022-09-22 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
US20230270670A1 (en) * 2020-07-24 2023-08-31 Pangen Biotech Inc. Ophthalmic liquid composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759472B2 (en) * 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
HUE053612T2 (en) * 2006-06-16 2021-07-28 Regeneron Pharma Vegf antagonist formulations suitable for intravitreal administration
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
BR112013004581A2 (en) * 2010-08-26 2017-06-27 Abbvie Inc dual variable domain immunoglobulins and their uses

Also Published As

Publication number Publication date
MX2014014445A (en) 2015-08-14
PH12014502577A1 (en) 2015-01-21
JP2015519373A (en) 2015-07-09
EA201492289A1 (en) 2015-05-29
US20150182623A1 (en) 2015-07-02
AU2013267310A1 (en) 2014-12-11
EP2854844A2 (en) 2015-04-08
WO2013181495A2 (en) 2013-12-05
EP2854844A4 (en) 2016-11-23
CL2014003233A1 (en) 2015-06-19
WO2013181495A3 (en) 2014-02-13
CN104619335A (en) 2015-05-13
KR20150033620A (en) 2015-04-01
IL235797A0 (en) 2015-01-29
AR091237A1 (en) 2015-01-21
HK1207983A1 (en) 2016-02-19
CA2874412A1 (en) 2013-12-05
TW201400122A (en) 2014-01-01
CO7240393A2 (en) 2015-04-17

Similar Documents

Publication Publication Date Title
SG11201407981RA (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201811490XA (en) Cd3 binding antibodies
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201407372UA (en) Nampt inhibitors
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201407682TA (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407789RA (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
SG11201407028WA (en) St2l antagonists and methods of use
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408261UA (en) Syringe
SG11201407486PA (en) Compositions and methods for modulating utrn expression